NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER (NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER).
Normosol-M and Dextrose 5% is a balanced electrolyte solution with dextrose. It provides free water, electrolytes, and a source of calories. The dextrose is metabolized to carbon dioxide and water, producing energy. The electrolytes help maintain or restore extracellular fluid balance.
| Metabolism | Dextrose is metabolized via glycolysis and Krebs cycle, producing ATP. Acetate and gluconate are converted to bicarbonate in the liver, helping to correct acidosis. |
| Excretion | Renal: Electrolytes and dextrose are excreted renally; dextrose is metabolized to CO2 and water, with no significant fecal or biliary elimination. |
| Half-life | Not applicable; components are endogenous substances with rapid clearance; dextrose half-life ~15-30 min in normal glucose metabolism. |
| Protein binding | Minimal; dextrose and electrolytes exhibit negligible protein binding (<5%). |
| Volume of Distribution | Electrolytes distribute in total body water (0.55-0.65 L/kg); dextrose distributes in extracellular fluid initially then intracellular. |
| Bioavailability | Intravenous: 100%. |
| Onset of Action | Intravenous: Immediate upon infusion (rapid correction of fluid and electrolyte imbalances). |
| Duration of Action | Duration depends on infusion rate; clinical effects persist as long as infusion continues; transient after discontinuation. |
| Molecular Weight | 180.16 |
Intravenous infusion; dose determined by fluid and electrolyte needs; typical adult rate: 100-200 mL/hour; maximum rate dependent on clinical condition.
| Dosage form | INJECTABLE |
| Renal impairment | In renal impairment (GFR <30 mL/min), reduce infusion rate and monitor for electrolyte imbalance; avoid in severe renal failure with oliguria. |
| Liver impairment | No specific adjustment; monitor electrolytes in severe hepatic impairment due to risk of fluid overload. |
| Pediatric use | Intravenous infusion; dose individualized based on weight and clinical needs; typical rate: 5-10 mL/kg/hour; maximum rate not to exceed 100 mL/hour in neonates. |
| Geriatric use | Use with caution; lower initial infusion rates recommended due to decreased renal function and risk of fluid overload; monitor closely. |
| 1st trimester | Normosol-M and Dextrose 5% contains electrolytes and dextrose. Dextrose is generally safe in pregnancy, but electrolyte imbalances may affect fetal development. Use only if clearly needed. |
| 2nd trimester | Similar to T1. Monitor maternal electrolytes and glucose. Use with caution. |
| 3rd trimester | High glucose loads may cause fetal hyperinsulinemia and neonatal hypoglycemia. Use only if benefits outweigh risks. |
Clinical note
Comprehensive clinical and safety monograph for NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER (NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER).
| Placental transfer | Dextrose and electrolytes readily cross the placenta. Degree depends on maternal levels and placental function. |
| Breastfeeding | Normosol-M and Dextrose 5% components are normal blood constituents. Dextrose and electrolytes enter breast milk in low amounts. Generally considered compatible with breastfeeding, but monitor infant for electrolyte imbalance if high volumes are infused. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | No evidence of teratogenicity in first trimester; dextrose may cause fetal hyperinsulinemia and macrosomia in second/third trimester if maternal hyperglycemia occurs; electrolyte imbalances may affect fetal homeostasis. |
| Fetal Monitoring | Monitor maternal blood glucose, serum electrolytes, fluid balance, and urine output; fetal surveillance for growth abnormalities and polyhydramnios if prolonged use. |
| Fertility Effects | No known adverse effects on fertility; used for fluid and electrolyte maintenance, not associated with reproductive toxicity. |
■ FDA Black Box Warning
WARNING: NOT FOR USE IN PATIENTS WITH KNOWN ALLERGY TO CORN OR CORN PRODUCTS. SOLUTIONS CONTAINING DEXTROSE MAY BE CONTRAINDICATED IN PATIENTS WITH HYPERSENSITIVITY TO CORN.
| Serious Effects |
HyperglycemiaSevere electrolyte disturbancesRenal failure with oliguria
| Precautions | Risk of fluid overload in patients with renal impairment or heart failure, Electrolyte imbalances (e.g., hyperkalemia, hyponatremia) with improper use, Hyperglycemia in diabetic patients; monitor blood glucose, Extravasation may cause tissue damage, Do not administer simultaneously with blood via same IV line (risk of hemolysis) |
| Food/Dietary | No known food interactions with this intravenous solution. However, oral intake may be restricted based on underlying condition. Monitor blood glucose if patient is eating while receiving dextrose. |
| Clinical Pearls | Normosol-M and Dextrose 5% is an isotonic solution containing multiple electrolytes and dextrose. Monitor serum glucose closely in diabetic patients due to dextrose content. Avoid use in patients with hyperkalemia, hypermagnesemia, or hypercalcemia. Contraindicated in patients with known allergies to corn (dextrose source). Use with caution in renal impairment, heart failure, or conditions causing fluid overload. Do not administer simultaneously with blood products; may cause agglutination. Inspect for particulate matter or discoloration before use. |
| Patient Advice | This solution provides fluids, sugars, and electrolytes to correct imbalances. · Tell your doctor if you have diabetes, kidney disease, heart failure, or allergies to corn. · Report any signs of allergic reaction: rash, itching, swelling, trouble breathing. · Inform your doctor if you experience swelling, shortness of breath, or irregular heartbeat. · You may need blood tests to monitor your glucose and electrolyte levels. |
Loading safety data…